Invokana (canagliflozin) is an SGLT2 inhibitor approved for type 2 diabetes, with added indications for cardiovascular protection and slowing chronic kidney disease. Its side effects fall into predictable categories: genital and urinary infections from glucose in the urine, dehydration and electrolyte shifts from increased urination, rare but serious metabolic events like euglycemic DKA, and drug-specific signals around amputation and bone fracture seen in the CANVAS trial. Most users tolerate Invokana well; the issues that matter most are the ones tied to specific risk profiles.
How Invokana Causes Its Side Effects
Invokana blocks the SGLT2 transporter in the kidney, preventing glucose reabsorption. The result is glucosuria — about 60 to 80 grams of glucose per day excreted in the urine. That single mechanism drives almost every side effect:
- Sugar in the urine feeds Candida yeast and bacteria, raising infection risk
- Osmotic diuresis (sugar pulls water) increases urination and lowers blood volume
- Reduced blood volume can drop blood pressure and stress the kidneys
- Shift toward fat metabolism in some conditions can trigger ketoacidosis
- Mineral handling shifts modestly affect magnesium, potassium, and calcium
Understanding the mechanism explains why dose matters, why hydration matters, and why illness or fasting can tip a stable user into trouble.
Common Side Effects
| Side Effect | Approximate Frequency | Notes |
|---|---|---|
| Genital yeast infection | 10–15% women, 4–8% men | Higher in uncircumcised men; recurrent cases may prompt switch |
| Urinary tract infection | 5–10% | Usually mild; recurrent UTIs warrant evaluation |
| Increased urination | ~5% | Usually settles after 2–4 weeks |
| Thirst | ~3% | Encourage water intake; watch for dehydration |
| Constipation | 2–4% | Often from inadequate fluid intake |
| Nausea | 2–3% | Usually mild and transient |
| Mild eGFR decline | Expected | 3–5 mL/min initial drop that stabilizes |
Genital and Urinary Infections
Glucose-rich urine feeds yeast and bacteria. Practical management:
- Gentle daily washing of the genital area, especially after sweating or exercise
- Air-dry rather than rub-dry after showering when possible
- Drink enough water that urine stays pale yellow
- For women: cotton underwear, avoid tight synthetic fabrics, no scented feminine products
- For uncircumcised men: retract and clean under the foreskin daily
- Topical antifungal creams (clotrimazole, miconazole) clear most yeast infections in 7 days
- Recurrent infections (more than 3 per year) may justify switching to a non-SGLT2 agent
Volume Depletion and Hypotension
Invokana acts as a mild diuretic. Symptoms of volume depletion include lightheadedness on standing, increased thirst, dry mouth, dark urine, and fatigue. Higher-risk groups:
- Adults over 65
- Users on ACE inhibitors, ARBs, or thiazide/loop diuretics
- People with chronic kidney disease (eGFR under 60)
- Anyone with reduced fluid intake from illness or hot weather
Most clinicians review and sometimes reduce the dose of other antihypertensives or diuretics when starting Invokana.
Euglycemic Diabetic Ketoacidosis (DKA)
Rare but serious — Invokana can trigger DKA with relatively normal blood glucose levels (often under 250 mg/dL), which delays diagnosis. Triggers include prolonged fasting, very low-carb diets, surgery, severe illness, alcohol binges, and reduced insulin doses in type 1 diabetes (off-label use). Warning signs:
- Nausea and vomiting
- Abdominal pain
- Unusual fatigue or shortness of breath
- Fruity breath odor
- Confusion
Stop Invokana and seek urgent evaluation if these appear, even if your meter reads normal. Hold Invokana for at least 3 days before scheduled surgery.
The CANVAS Amputation Signal
The CANVAS program (Neal et al., NEJM 2017) reported about double the rate of lower-limb amputations with canagliflozin (6.3 vs 3.4 per 1,000 patient-years), mostly toe and midfoot. The mechanism is unclear — possibly volume depletion in already-compromised limbs. The FDA added a box warning in 2017, then removed it in 2020 after CREDENCE (Perkovic et al., NEJM 2019) did not replicate the signal. Current practice:
- Avoid in patients with active foot ulcers or recent amputation
- Use caution in severe peripheral artery disease or advanced neuropathy
- Encourage regular foot exams and prompt reporting of new pain, sores, or color changes
- Stop temporarily if a foot wound develops, until healed
Bone Fracture Risk
CANVAS also found about a 1.5-fold increase in fracture risk (mostly upper extremity, after falls), seen as early as 12 weeks of treatment. The signal was not seen with other SGLT2 inhibitors in their respective trials. Possible mechanisms include modest calcium and magnesium shifts and bone density effects. Consider an alternative SGLT2 inhibitor in users with osteoporosis or high fall risk.
Other Less Common Effects
- Hyperkalemia — small rise in potassium, more likely with ACE/ARB or potassium-sparing diuretics
- Fournier gangrene — very rare necrotizing infection of the perineum; severe pain, redness, swelling, and fever require emergency care
- Mild LDL cholesterol increase — typically 4 to 8 percent, clinically modest
- Photosensitivity rash — rare
- Slight hematocrit increase — usually benign, sometimes flagged on labs
Dose Matters: 100 mg vs 300 mg
| Effect | 100 mg | 300 mg |
|---|---|---|
| A1C reduction | ~0.7% | ~0.9% |
| Weight loss | ~2–3 kg | ~3–4 kg |
| Yeast infection rate (women) | ~10% | ~14% |
| Volume depletion | ~1% | ~2% |
| Renal-related events | ~2% | ~3% |
Most users start at 100 mg and escalate only if A1C control needs more help and side effects have been mild.
Sick-Day and Surgery Plan
- Hold Invokana during vomiting, severe diarrhea, or any inability to eat and drink normally
- Hold for at least 3 days before scheduled surgery (4 days for major surgery)
- Resume only after eating and drinking are normal and any acute illness is resolving
- Maintain fluid intake aggressively in hot weather or during heavy exercise
Monitoring While on Invokana
- eGFR and serum creatinine at baseline, 1 month, then every 3 to 6 months
- Electrolytes (potassium, magnesium) periodically
- A1C every 3 to 6 months
- Foot exam at every clinical visit
- Blood pressure at home if also on antihypertensives
- Reporting of any genitourinary symptoms early
Comparison with Other SGLT2 Inhibitors
| Drug | Amputation Signal | Fracture Signal | HF/CV Benefit |
|---|---|---|---|
| Invokana (canagliflozin) | Yes (CANVAS) | Yes (CANVAS) | Yes |
| Jardiance (empagliflozin) | No | No | Yes (strong) |
| Farxiga (dapagliflozin) | No | No | Yes (strong) |
| Steglatro (ertugliflozin) | No | No | HF only |
Related Reading
For broader context see our treatment overview, our deep dive on Invokana (canagliflozin), the class-level SGLT2 inhibitor side effects guide, and the complete SGLT2 inhibitors list. Compare with peers in empagliflozin vs dapagliflozin. External references: the CANVAS trial in NEJM and the ADA Standards of Care.
The Bottom Line
Invokana side effects cluster predictably around its mechanism: genital yeast infections (10 to 15 percent), urinary tract infections (5 to 10 percent), and dehydration from sugar-driven urination. Serious but rare events include euglycemic DKA, Fournier gangrene, acute kidney injury, and the CANVAS-era amputation and fracture signals. Risk is largely dose dependent and concentrated in users with peripheral artery disease, advanced CKD, on multiple antihypertensives, or unable to maintain hydration. Sick-day rules and a foot exam at every visit handle most of the residual concern.
